Related Experiment Video

Updated: Jun 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Infectious pulmonary complications of rheumatic diseases]

F Moosig1, K Dalhoff

  • 1Klinikum Bad Bramstedt, Klinik für Rheumatologie und Klinische Immunologie, Poliklinik für Rheumatologie, Universitätsklinikum Schleswig Holstein, Bad Bramstedt, Deutschland. moosig@klinikumbb.de

Zeitschrift Fur Rheumatologie
|August 6, 2009
PubMed

Insights

Patients with rheumatic diseases face high infection risks due to immunosuppressants. Prophylaxis for tuberculosis and Pneumocystis pneumonia is recommended in specific high-risk scenarios.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Pharmacology

Context:

  • Infectious complications are a significant challenge in managing rheumatic diseases.
  • Immunosuppressive therapies, especially glucocorticoids, increase infection susceptibility.
  • Aggressive diagnostics, including bronchoscopy, are often required for microbiological analysis.

Purpose:

  • To highlight key opportunistic infections in immunosuppressed rheumatic disease patients.
  • To discuss the role of anti-infective chemoprophylaxis in specific contexts.
  • To emphasize the importance of tailored prophylactic strategies.

Summary:

  • Rheumatic disease patients on immunosuppressants are prone to infections like Pneumocystis jirovecii pneumonia (PCP), invasive aspergillosis, CMV reactivation, and tuberculosis (TB).
  • Failure of empiric antibiotic therapy in immunocompromised individuals correlates with increased mortality.
  • Prophylaxis is established for latent TB with isoniazid (INH) before anti-TNF therapy and for PCP with trimethoprim/cotrimoxazole in patients on high-dose glucocorticoids and cyclophosphamide.

Impact:

  • Informed clinical decisions regarding infection risk assessment and management in rheumatic disease patients.
  • Improved patient outcomes through targeted prophylactic interventions.
  • Reduced morbidity and mortality associated with opportunistic infections in this vulnerable population.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...